Theriva Total Liab vs Cash And Short Term Investments Analysis

TOVX Stock  USD 1.28  0.02  1.59%   
Theriva Biologics financial indicator trend analysis is much more than just breaking down Theriva Biologics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Theriva Biologics is a good investment. Please check the relationship between Theriva Biologics Total Liab and its Cash And Short Term Investments accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theriva Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Total Liab vs Cash And Short Term Investments

Total Liab vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Theriva Biologics Total Liab account and Cash And Short Term Investments. At this time, the significance of the direction appears to have very week relationship.
The correlation between Theriva Biologics' Total Liab and Cash And Short Term Investments is 0.2. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Theriva Biologics, assuming nothing else is changed. The correlation between historical values of Theriva Biologics' Total Liab and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Theriva Biologics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Liab i.e., Theriva Biologics' Total Liab and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.2
Relationship DirectionPositive 
Relationship StrengthVery Weak

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Theriva Biologics balance sheet. This account contains Theriva Biologics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Theriva Biologics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Theriva Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Theriva Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theriva Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.At this time, Theriva Biologics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.75 in 2024, whereas Selling General Administrative is likely to drop slightly above 7.1 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses14.3M21.6M21.4M13.9M
Cost Of Revenue87K268K135K183.7K

Theriva Biologics fundamental ratios Correlations

0.140.94-0.83-0.760.010.790.730.790.860.460.810.120.84-0.51-0.760.540.90.480.460.53-0.350.36-0.270.510.71
0.14-0.14-0.14-0.20.740.140.00.140.160.790.210.990.15-0.130.060.330.040.04-0.070.11-0.280.270.09-0.13-0.01
0.94-0.14-0.84-0.68-0.180.820.620.820.790.130.81-0.150.72-0.44-0.760.40.820.380.390.33-0.290.29-0.30.630.61
-0.83-0.14-0.840.56-0.01-0.99-0.23-0.99-0.64-0.23-0.98-0.13-0.50.390.55-0.26-0.560.00.01-0.190.32-0.320.06-0.79-0.21
-0.76-0.2-0.680.56-0.16-0.54-0.64-0.54-0.98-0.51-0.55-0.14-0.840.350.83-0.63-0.74-0.53-0.49-0.530.52-0.520.49-0.38-0.62
0.010.74-0.18-0.01-0.160.01-0.130.010.10.550.10.640.030.00.160.24-0.12-0.1-0.150.01-0.230.24-0.02-0.14-0.14
0.790.140.82-0.99-0.540.010.191.00.610.20.990.140.45-0.41-0.530.210.530.0-0.070.16-0.320.3-0.050.780.17
0.730.00.62-0.23-0.64-0.130.190.190.710.480.21-0.020.85-0.45-0.660.590.880.850.80.73-0.20.21-0.39-0.071.0
0.790.140.82-0.99-0.540.011.00.190.610.20.990.140.45-0.41-0.530.210.530.0-0.070.16-0.320.3-0.050.780.17
0.860.160.79-0.64-0.980.10.610.710.610.50.610.10.89-0.38-0.860.650.820.550.540.56-0.490.5-0.470.440.68
0.460.790.13-0.23-0.510.550.20.480.20.50.250.770.57-0.33-0.260.560.450.40.30.69-0.320.33-0.05-0.140.47
0.810.210.81-0.98-0.550.10.990.210.990.610.250.20.46-0.42-0.530.250.540.03-0.050.16-0.350.33-0.070.750.19
0.120.99-0.15-0.13-0.140.640.14-0.020.140.10.770.20.12-0.120.080.30.020.01-0.090.09-0.250.240.13-0.13-0.03
0.840.150.72-0.5-0.840.030.450.850.450.890.570.460.12-0.27-0.740.640.920.710.760.7-0.320.33-0.30.310.83
-0.51-0.13-0.440.390.350.0-0.41-0.45-0.41-0.38-0.33-0.42-0.12-0.270.40.04-0.33-0.160.12-0.420.09-0.090.20.03-0.46
-0.760.06-0.760.550.830.16-0.53-0.66-0.53-0.86-0.26-0.530.08-0.740.4-0.42-0.76-0.52-0.56-0.440.42-0.420.43-0.49-0.65
0.540.330.4-0.26-0.630.240.210.590.210.650.560.250.30.640.04-0.420.660.60.60.45-0.590.61-0.51-0.020.56
0.90.040.82-0.56-0.74-0.120.530.880.530.820.450.540.020.92-0.33-0.760.660.770.750.63-0.440.43-0.420.310.86
0.480.040.380.0-0.53-0.10.00.850.00.550.40.030.010.71-0.16-0.520.60.770.840.59-0.290.21-0.41-0.220.85
0.46-0.070.390.01-0.49-0.15-0.070.8-0.070.540.3-0.05-0.090.760.12-0.560.60.750.840.49-0.20.22-0.34-0.030.8
0.530.110.33-0.19-0.530.010.160.730.160.560.690.160.090.7-0.42-0.440.450.630.590.49-0.130.13-0.09-0.090.72
-0.35-0.28-0.290.320.52-0.23-0.32-0.2-0.32-0.49-0.32-0.35-0.25-0.320.090.42-0.59-0.44-0.29-0.2-0.13-0.980.8-0.11-0.17
0.360.270.29-0.32-0.520.240.30.210.30.50.330.330.240.33-0.09-0.420.610.430.210.220.13-0.98-0.810.120.18
-0.270.09-0.30.060.49-0.02-0.05-0.39-0.05-0.47-0.05-0.070.13-0.30.20.43-0.51-0.42-0.41-0.34-0.090.8-0.810.15-0.38
0.51-0.130.63-0.79-0.38-0.140.78-0.070.780.44-0.140.75-0.130.310.03-0.49-0.020.31-0.22-0.03-0.09-0.110.120.15-0.09
0.71-0.010.61-0.21-0.62-0.140.171.00.170.680.470.19-0.030.83-0.46-0.650.560.860.850.80.72-0.170.18-0.38-0.09
Click cells to compare fundamentals

Theriva Biologics Account Relationship Matchups

Theriva Biologics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets17.2M8.4M70.4M71.9M55.2M58.0M
Total Current Liabilities5.3M3.0M3.6M7.1M6.7M4.2M
Total Stockholder Equity14.4M8.0M65.4M54.6M39.7M41.7M
Net Debt(14.3M)(5.8M)(65.8M)(40.1M)(21.0M)(20.0M)
Retained Earnings(235.5M)(248.1M)(271.3M)(291.0M)(309.3M)(293.9M)
Accounts Payable2.3M886K524K915K770K1.1M
Cash15.0M6.2M67.3M41.8M23.2M12.9M
Non Current Assets Total809K476K1.5M26.3M27.8M29.2M
Cash And Short Term Investments15.0M6.2M67.3M41.8M23.2M13.0M
Liabilities And Stockholders Equity17.2M8.4M70.4M71.9M55.2M58.0M
Other Stockholder Equity232.6M240.8M336.6M343.5M346.2M363.5M
Total Liab5.7M3.2M5.0M17.3M15.5M16.3M
Total Current Assets16.4M7.9M68.9M45.5M27.4M14.4M
Other Current Liab2.7M1.8M2.9M5.7M4.9M3.0M
Property Plant And Equipment Net786K453K1.5M1.5M2.2M2.3M
Non Current Liabilities Total473K186K1.4M10.2M8.8M9.2M
Common Stock17K29K132K16K18K17.1K
Common Stock Shares Outstanding1.6M1.9M12.2M613.1K644.3K1.1M
Net Tangible Assets(2.9M)(7.2M)65.4M46.3M53.3M55.9M
Net Invested Capital(2.9M)(7.2M)65.4M52.1M37.2M28.6M
Capital Stock17.3M15.3M132K2.8M2.8M2.6M
Net Working Capital11.2M5.0M65.3M38.5M20.7M30.6M
Property Plant Equipment786K453K1.5M1.5M1.8M1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.